Table 2 Clinical information of patients in the TCGA training dataset and GSE62254 validation dataset
Clinical characteristics | TCGA (N = 360) | GSE62254 (N = 300) |
|---|---|---|
Age (years, mean ± sd) | 64.9 ± 10.39 | 61.94 ± 11.36 |
Gender (male/female) | 234/126 | 199/101 |
Pathologic_M (M0/M1/–) | 328/18/14 | 273/27 |
Pathologic_N (N0/N1/N2/N3) | 113/94/72/75/6 | 38/131/80/51 |
Pathologic_T (T1/T2/T3/T4/–) | 17/70/167/105/1 | 2/186/91/21 |
Pathologic_stage (I/II/III/IV/–) | 47/113/170/29/1 | 30/96/95/77/2 |
Targeted molecular therapy (yes/no/–) | 144/193/23 | – |
Recurrence (yes/no) | 77/253/30 | 125/157/18 |
Dead (death/alive/–) | 122/238 | 135/148//17 |
Disease free survival (months, mean ± sd) | 18.57 ± 17.19 | 33.72 ± 29.82 |
Overall survival time (months, mean ± sd) | 16.17 ± 16.95 | 50.59 ± 31.42 |